| Project/Area Number |
17K11148
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | Kagoshima University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
吉野 裕史 鹿児島大学, 医歯学域鹿児島大学病院, 助教 (90642611)
|
|---|
| Project Period (FY) |
2017-04-01 – 2020-03-31
|
| Project Status |
Completed (Fiscal Year 2019)
|
| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2019: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Keywords | マイクロRNA / 腎癌 / CRISPR/Cas9 / microRNA / 膀胱癌 / ゲノム編集 |
|---|
| Outline of Final Research Achievements |
As results of research, we found that microRNA-210 (miR-210) was highly expressed in renal cancers compared to normal kidneys by the array analysis using normal kidneys and kidney cancer clinical specimens. miR-210 expression was almost depleted by using CRISPR/Cas9. It was revealed that miR-210 regulated TWIST1 directly by the target gene search. In addition, we confirmed that miR-1274 was highly expressed in kidney cancers compared to normal kidneys, and identified BMPR1B which was an osteoplasty protein receptor as the target gene. In summary, we showed a functional analysis and a target gene of highly expressed micro RNA in renal cancer.
|
| Academic Significance and Societal Importance of the Research Achievements |
進行性腎癌の多くは分子標的治療薬に治療抵抗性を獲得し、再発・転移に至る。マイクロRNAは遺伝子の発現調節に寄与することが知られており、今まで癌に関与するマイクロRNAに関して多くの報告がなされてきた。しかし、癌部で発現が亢進しているマイクロRNAに関しての報告は限定的であった。本研究により、癌促進型マイクロRNAの機能解析と標的遺伝子を示すことができ、進行性腎癌に対する新たな理解と治療戦略の可能性が提案された。
|
